Aclaris Therapeutics, Inc.
$5.50
Market Cap
$809.59M
Shares Outstanding
147.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 7, 2015
Round Lot
100
Locale
US
Day Open
$5.41
Day High
$5.54
Day Low
$5.36
Volume
4.69M
VWAP
$5.48
Prev Close
$5.40
Transactions
--
Acc. Volume
--
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Aclaris Therapeutics, Inc. (ACRS) closed the 2026-09-18 session at $5.50, up 1.85% versus the previous close (+0.10). The stock opened at $5.41 and traded between $5.36 and $5.54 during that session. Session trading volume was 4.7M shares. The volume-weighted average price (VWAP) is $5.48.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Aclaris Therapeutics, Inc. has a market capitalization of $809.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ACRS is listed on the XNAS exchange. The company employs approximately 73 people. Aclaris Therapeutics, Inc. is headquartered in WAYNE, PA. The recorded listing date is 2015-10-07.
On this page you can find market ACRS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.